Thesis
Given GSK's recent $2.2 billion settlement of Zantac lawsuits and its successful phase 3 trials for depemokimab, I believe the stock is positioned for short-term growth. However, the ongoing market volatility and litigation concerns present significant risks, making it a potential short opportunity as well.